Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder
European Child and Adolescent Psychiatry, Volume 15, No. 2, Year 2006
Notification
URL copied to clipboard!
Description
Objective: To examine the influence of comorbid oppositional defiant disorder (ODD) on the relative risk (RR) of relapse during 9 months of treatment with atomoxetine for attention-deficit/ hyperactivity disorder (ADHD). Method: Four hundred and sixteen children and adolescents with ADHD whose symptoms remitted during initial 10-week, open-label atomoxetine treatment were randomly assigned to continue with atomoxetine or placebo. Results: In all, 43 % met criteria for comorbid ODD. A total of 17 % of patients with comorbid ODD relapsed (CGI-Severity score ≥ 3 and ADHD Rating Scale total score of 90 % or more of baseline at study entry on two consecutive visits) during atomoxetine treatment, compared with 26 % of patients without comorbid ODD (RR 0.67, 95 % CI 0.42-1.06). Mean time to relapse was not significantly different [mean (SE) days to relapse, ADHD/ +ODD: 215 (7.38); ADHD/-ODD: 211 (7.61); log rank p = 0.08]. This finding is placed within the context of atomoxetine affording an overall protection against relapse compared with placebo (RR 0.59, 95 % CI 0.43-0.80). Conclusions: Comorbid ODD does not influence the rate of relapse of patients with ADHD during longer-term treatment with atomoxetine. Atomoxetine protects against the relapse of ADHD symptoms regardless of the presence or absence of comorbid ODD. © Steinkopff Verlag 2006.
Authors & Co-Authors
Hazell, Philip L.
Australia, Callaghan
The University of Newcastle, Australia
Zhang, Shuyu
United States, Indianapolis
Eli Lilly and Company
Wolańczyk, Tomasz
Poland, Warsaw
Medical University of Warsaw
Barton, Joanne
United Kingdom, Stoke-on-trent
North Staffordshire Combined Healthcare Nhs Trust
Johnson, Mats
Sweden, Gothenburg
Barnneuropsykiatriska Kliniken
Zuddas, Alessandro
Italy, Cagliari
Università Degli Studi Di Cagliari
Danckaerts, Marina
Belgium, Leuven
Ku Leuven
Ladikos, Andrula
South Africa, Pretoria
Denmar Psychiatric Hospital
Benn, David
Unknown Affiliation
Yoran-Hegesh, Roni
Israel, Nes Ziona
Psychiatric Hospital
Zeiner, Pal
Norway, Oslo
Statens Senter for Barne- og Ungdomspsykiatri
Michelson, David
United States, Indianapolis
Eli Lilly and Company
Statistics
Citations: 73
Authors: 12
Affiliations: 10
Identifiers
Doi:
10.1007/s00787-006-0506-y
ISSN:
10188827
e-ISSN:
1435165X
Research Areas
Maternal And Child Health